Baseline patient and ALL characteristics of Hispanic, NHW, and NHB patients enrolled on CALGB 10403
| . | NHW (n = 172) . | Hispanic (n = 45) . | NHB (n = 25) . | P . |
|---|---|---|---|---|
| Age, years, no. (%) | .45 | |||
| 15-19.9 | 40 (23) | 11 (24) | 9 (36) | |
| 20-24.9 | 47 (27) | 18 (40) | 7 (28) | |
| 25-29.9 | 42 (24) | 9 (20) | 6 (24) | |
| 30-34.9 | 28 (16) | 3 (7) | 1 (4) | |
| 35-39.0 | 15 (9) | 4 (9) | 2 (8) | |
| Sex, no. (%) | .64 | |||
| Male | 102 (59) | 30 (67) | 16 (64) | |
| Female | 70 (41) | 15 (33) | 9 (36) | |
| BMI, no. (%) | .86 | |||
| Underweight | 3 (2) | 0 | 1 (4) | |
| Normal | 66 (38) | 17 (38) | 9 (36) | |
| Overweight | 46 (27) | 11 (24) | 8 (32) | |
| Obese | 57 (33) | 17 (38) | 7 (28) | |
| Yearly household income, no. (%) | .003 | |||
| < $20 000 | 36 (29) | 19 (61) | 11 (69) | |
| $20 000 to $49 000 | 35 (28) | 7 (23) | 3 (19) | |
| $50 000 to $74 999 | 19 (15) | 3 (10) | 2 (13) | |
| $75 000 to $99 000 | 20 (16) | 0 | 0 | |
| ≥ $100 000 | 16 (13) | 2 (7) | 0 | |
| Missing (n) | 46 | 14 | 9 | |
| Immunophenotype, no. (%) | <.001 | |||
| B-cell ALL | 133 (77) | 44 (98) | 11 (44) | |
| T-cell ALL | 39 (23) | 1 (2) | 14 (56) | |
| WBC at Dx, ×106/uL, No. (%) | .09 | |||
| ≤30 | 134 (79) | 29 (64) | 17 (68) | |
| 30 | 36 (21) | 16 (36) | 8 (32) | |
| Missing (n) | 2 | 0 | 0 | |
| Cytogenetics, no. (%) | .69 | |||
| Favorable | 11 (13) | 3 (16) | 1 (8) | |
| Intermediate | 60 (69) | 15 (79) | 10 (83) | |
| Unfavorable | 16 (18) | 1 (5) | 1 (8) | |
| Missing (n) | 85 (49) | 26 (58) | 13 (52) | |
| Ph-like, no. (%) | .09 | |||
| No | 57 (74) | 12 (55) | 5 (50) | |
| Yes | 20 (26) | 10 (46) | 5 (50) | |
| Missing (n) | 95 | 23 | 15 | |
| CRLF2 aberration, no. (%) | .03 | |||
| No | 65 (84) | 13 (59) | 8 (80) | |
| Yes | 12 (16) | 9 (41) | 2 (20) | |
| Missing (n) | 95 | 23 | 15 |
| . | NHW (n = 172) . | Hispanic (n = 45) . | NHB (n = 25) . | P . |
|---|---|---|---|---|
| Age, years, no. (%) | .45 | |||
| 15-19.9 | 40 (23) | 11 (24) | 9 (36) | |
| 20-24.9 | 47 (27) | 18 (40) | 7 (28) | |
| 25-29.9 | 42 (24) | 9 (20) | 6 (24) | |
| 30-34.9 | 28 (16) | 3 (7) | 1 (4) | |
| 35-39.0 | 15 (9) | 4 (9) | 2 (8) | |
| Sex, no. (%) | .64 | |||
| Male | 102 (59) | 30 (67) | 16 (64) | |
| Female | 70 (41) | 15 (33) | 9 (36) | |
| BMI, no. (%) | .86 | |||
| Underweight | 3 (2) | 0 | 1 (4) | |
| Normal | 66 (38) | 17 (38) | 9 (36) | |
| Overweight | 46 (27) | 11 (24) | 8 (32) | |
| Obese | 57 (33) | 17 (38) | 7 (28) | |
| Yearly household income, no. (%) | .003 | |||
| < $20 000 | 36 (29) | 19 (61) | 11 (69) | |
| $20 000 to $49 000 | 35 (28) | 7 (23) | 3 (19) | |
| $50 000 to $74 999 | 19 (15) | 3 (10) | 2 (13) | |
| $75 000 to $99 000 | 20 (16) | 0 | 0 | |
| ≥ $100 000 | 16 (13) | 2 (7) | 0 | |
| Missing (n) | 46 | 14 | 9 | |
| Immunophenotype, no. (%) | <.001 | |||
| B-cell ALL | 133 (77) | 44 (98) | 11 (44) | |
| T-cell ALL | 39 (23) | 1 (2) | 14 (56) | |
| WBC at Dx, ×106/uL, No. (%) | .09 | |||
| ≤30 | 134 (79) | 29 (64) | 17 (68) | |
| 30 | 36 (21) | 16 (36) | 8 (32) | |
| Missing (n) | 2 | 0 | 0 | |
| Cytogenetics, no. (%) | .69 | |||
| Favorable | 11 (13) | 3 (16) | 1 (8) | |
| Intermediate | 60 (69) | 15 (79) | 10 (83) | |
| Unfavorable | 16 (18) | 1 (5) | 1 (8) | |
| Missing (n) | 85 (49) | 26 (58) | 13 (52) | |
| Ph-like, no. (%) | .09 | |||
| No | 57 (74) | 12 (55) | 5 (50) | |
| Yes | 20 (26) | 10 (46) | 5 (50) | |
| Missing (n) | 95 | 23 | 15 | |
| CRLF2 aberration, no. (%) | .03 | |||
| No | 65 (84) | 13 (59) | 8 (80) | |
| Yes | 12 (16) | 9 (41) | 2 (20) | |
| Missing (n) | 95 | 23 | 15 |
BMI, body mass index; No., number; WBC, white blood cell.